EDSA vs. ONCT, PTI, ANEB, HOOK, PRPH, ALRN, RMTI, MURA, LPTX, and CELU
Should you be buying Edesa Biotech stock or one of its competitors? The main competitors of Edesa Biotech include Oncternal Therapeutics (ONCT), Proteostasis Therapeutics (PTI), Anebulo Pharmaceuticals (ANEB), Hookipa Pharma (HOOK), ProPhase Labs (PRPH), Aileron Therapeutics (ALRN), Rockwell Medical (RMTI), Mural Oncology (MURA), Leap Therapeutics (LPTX), and Celularity (CELU). These companies are all part of the "medical" sector.
Edesa Biotech (NASDAQ:EDSA) and Oncternal Therapeutics (NASDAQ:ONCT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.
Edesa Biotech has higher earnings, but lower revenue than Oncternal Therapeutics.
Edesa Biotech currently has a consensus target price of $39.00, suggesting a potential upside of 619.56%. Oncternal Therapeutics has a consensus target price of $28.33, suggesting a potential upside of 301.89%. Given Edesa Biotech's stronger consensus rating and higher probable upside, equities research analysts clearly believe Edesa Biotech is more favorable than Oncternal Therapeutics.
In the previous week, Oncternal Therapeutics had 1 more articles in the media than Edesa Biotech. MarketBeat recorded 2 mentions for Oncternal Therapeutics and 1 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 1.89 beat Oncternal Therapeutics' score of 0.93 indicating that Edesa Biotech is being referred to more favorably in the media.
Oncternal Therapeutics received 5 more outperform votes than Edesa Biotech when rated by MarketBeat users. However, 76.47% of users gave Edesa Biotech an outperform vote while only 30.39% of users gave Oncternal Therapeutics an outperform vote.
Edesa Biotech has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Oncternal Therapeutics has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500.
Edesa Biotech has a net margin of 0.00% compared to Oncternal Therapeutics' net margin of -3,160.73%. Oncternal Therapeutics' return on equity of -107.67% beat Edesa Biotech's return on equity.
5.5% of Edesa Biotech shares are owned by institutional investors. Comparatively, 16.0% of Oncternal Therapeutics shares are owned by institutional investors. 25.0% of Edesa Biotech shares are owned by insiders. Comparatively, 11.2% of Oncternal Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Edesa Biotech beats Oncternal Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Edesa Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for EDSA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EDSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Edesa Biotech Competitors List
Related Companies and Tools
